BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 29558515)

  • 1. New drug candidates for treatment of atypical meningiomas: An integrated approach using gene expression signatures for drug repurposing.
    Zador Z; King AT; Geifman N
    PLoS One; 2018; 13(3):e0194701. PubMed ID: 29558515
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overexpression of eIF4F components in meningiomas and suppression of meningioma cell growth by inhibiting translation initiation.
    Oblinger JL; Burns SS; Huang J; Pan L; Ren Y; Shen R; Kinghorn AD; Welling DB; Chang LS
    Exp Neurol; 2018 Jan; 299(Pt B):299-307. PubMed ID: 28610844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel drug candidate for the treatment of several soft‑tissue sarcoma histologic subtypes: A computational method using survival‑associated gene signatures for drug repurposing.
    Yang X; Huang WT; Wu HY; He RQ; Ma J; Liu AG; Chen G
    Oncol Rep; 2019 Apr; 41(4):2241-2253. PubMed ID: 30816547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Weighted gene co-expression network analysis and connectivity map identifies lovastatin as a treatment option of gastric cancer by inhibiting HDAC2.
    Zhang L; Kang W; Lu X; Ma S; Dong L; Zou B
    Gene; 2019 Jan; 681():15-25. PubMed ID: 30266498
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simultaneous analysis of miRNA-mRNA in human meningiomas by integrating transcriptome: A relationship between PTX3 and miR-29c.
    Dalan AB; Gulluoglu S; Tuysuz EC; Kuskucu A; Yaltirik CK; Ozturk O; Ture U; Bayrak OF
    BMC Cancer; 2017 Mar; 17(1):207. PubMed ID: 28327132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Microarray-based gene expression profiling of benign, atypical and anaplastic meningiomas identifies novel genes associated with meningioma progression.
    Wrobel G; Roerig P; Kokocinski F; Neben K; Hahn M; Reifenberger G; Lichter P
    Int J Cancer; 2005 Mar; 114(2):249-56. PubMed ID: 15540215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel drug candidates for treating esophageal carcinoma: A study on differentially expressed genes, using connectivity mapping and molecular docking.
    Chen YT; Xie JY; Sun Q; Mo WJ
    Int J Oncol; 2019 Jan; 54(1):152-166. PubMed ID: 30387840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative proteomic profiles of meningioma subtypes.
    Okamoto H; Li J; Vortmeyer AO; Jaffe H; Lee YS; Gläsker S; Sohn TS; Zeng W; Ikejiri B; Proescholdt MA; Mayer C; Weil RJ; Oldfield EH; Zhuang Z
    Cancer Res; 2006 Oct; 66(20):10199-204. PubMed ID: 17047085
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Computational Drug Repositioning for Gastric Cancer using Reversal Gene Expression Profiles.
    Kim IW; Jang H; Kim JH; Kim MG; Kim S; Oh JM
    Sci Rep; 2019 Feb; 9(1):2660. PubMed ID: 30804389
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene expression profiles of metabolic aggressiveness and tumor recurrence in benign meningioma.
    Serna E; Morales JM; Mata M; Gonzalez-Darder J; San Miguel T; Gil-Benso R; Lopez-Gines C; Cerda-Nicolas M; Monleon D
    PLoS One; 2013; 8(6):e67291. PubMed ID: 23840654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Microarray gene expression profiling in meningiomas: differential expression according to grade or histopathological subtype.
    Fèvre-Montange M; Champier J; Durand A; Wierinckx A; Honnorat J; Guyotat J; Jouvet A
    Int J Oncol; 2009 Dec; 35(6):1395-407. PubMed ID: 19885562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrated genomic analyses of de novo pathways underlying atypical meningiomas.
    Harmancı AS; Youngblood MW; Clark VE; Coşkun S; Henegariu O; Duran D; Erson-Omay EZ; Kaulen LD; Lee TI; Abraham BJ; Simon M; Krischek B; Timmer M; Goldbrunner R; Omay SB; Baranoski J; Baran B; Carrión-Grant G; Bai H; Mishra-Gorur K; Schramm J; Moliterno J; Vortmeyer AO; Bilgüvar K; Yasuno K; Young RA; Günel M
    Nat Commun; 2017 Feb; 8():14433. PubMed ID: 28195122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medical management of meningiomas.
    Chukwueke UN; Wen PY
    Handb Clin Neurol; 2020; 170():291-302. PubMed ID: 32586501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro testing to a panel of potential chemotherapeutics and current concepts of chemotherapy in benign meningiomas.
    Balik V; Sulla I; Park HH; Sarissky M
    Surg Oncol; 2015 Sep; 24(3):292-9. PubMed ID: 26099192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Array expression meta-analysis of cancer stem cell genes identifies upregulation of PODXL especially in DCC low expression meningiomas.
    Schulten HJ; Hussein D
    PLoS One; 2019; 14(5):e0215452. PubMed ID: 31083655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First insight into the somatic mutation burden of neurofibromatosis type 2-associated grade I and grade II meningiomas: a case report comprehensive genomic study of two cranial meningiomas with vastly different clinical presentation.
    Dewan R; Pemov A; Dutra AS; Pak ED; Edwards NA; Ray-Chaudhury A; Hansen NF; Chandrasekharappa SC; Mullikin JC; Asthagiri AR; ; Heiss JD; Stewart DR; Germanwala AV
    BMC Cancer; 2017 Feb; 17(1):127. PubMed ID: 28193203
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNA microarray analysis identifies CKS2 and LEPR as potential markers of meningioma recurrence.
    Menghi F; Orzan FN; Eoli M; Farinotti M; Maderna E; Pisati F; Bianchessi D; Valletta L; Lodrini S; Galli G; Anghileri E; Pellegatta S; Pollo B; Finocchiaro G
    Oncologist; 2011; 16(10):1440-50. PubMed ID: 21948653
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential expression profiling analyses identifies downregulation of 1p, 6q, and 14q genes and overexpression of 6p histone cluster 1 genes as markers of recurrence in meningiomas.
    Pérez-Magán E; Rodríguez de Lope A; Ribalta T; Ruano Y; Campos-Martín Y; Pérez-Bautista G; García JF; García-Claver A; Fiaño C; Hernández-Moneo JL; Mollejo M; Meléndez B
    Neuro Oncol; 2010 Dec; 12(12):1278-90. PubMed ID: 20685720
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SCNrank: spectral clustering for network-based ranking to reveal potential drug targets and its application in pancreatic ductal adenocarcinoma.
    Liu E; Zhang ZZ; Cheng X; Liu X; Cheng L
    BMC Med Genomics; 2020 Apr; 13(Suppl 5):50. PubMed ID: 32241274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EPH receptor signaling as a novel therapeutic target in NF2-deficient meningioma.
    Angus SP; Oblinger JL; Stuhlmiller TJ; DeSouza PA; Beauchamp RL; Witt L; Chen X; Jordan JT; Gilbert TSK; Stemmer-Rachamimov A; Gusella JF; Plotkin SR; Haggarty SJ; Chang LS; Johnson GL; Ramesh V;
    Neuro Oncol; 2018 Aug; 20(9):1185-1196. PubMed ID: 29982664
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.